GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
CAMBRIDGE, England -- Businesswire -- Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.
Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing a fully automated data analysis application, aimed at transforming the usability and scalability of genomic data for routine oncology clinical practice.
To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with GenomOncology to provide regional therapy recommendations.
GenomOncology’s Precision Oncology Platform is designed to harmonize the latest precision oncology information, which includes an extensive set of annotations and ontologies, as well as curated public, licensed, and proprietary content and data sets. By incorporating this comprehensive knowledgebase, Congenica will have improved access to curated, precision oncology information from the United States, United Kingdom, European Union, and others, to yield data-driven insights and recommendations within their CDS.
Alistair Johnson, Chief Professional Services Officer at Congenica, said: “This collaboration signifies the expansion of Congenica’s Clinical Decision Support (CDS) Platform into oncology. Our novel product offers a fully automated future-proof end-to-end solution that unlocks the full potential of Next Generation Sequencing (NGS) in the clinical oncology space. GenomOncology brings extensive experience in precision oncology care, and its platform has been developed specifically to deliver clinical informatics solutions for cancer. We look forward to working with GenomOncology to further drive precision medicine, delivering high quality patient care and shaping the future of human health.”
“Our partnership with Congenica enables us to expand opportunities for precision oncology care at the global level. The extensive information available within the GenomOncology Precision Oncology Platform, combined with the capabilities of the Congenica Clinical Decision Support Platform, will give clinicians and researchers the knowledge needed to provide their patients with the most appropriate care opportunities,” said Brad Wertz, Chief Executive Officer at GenomOncology.
About Congenica Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers and clinicians to provide life-changing answers that improve wellbeing and disease management. Congenica’s world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.
A recognised leader in the genomic analysis of rare diseases and inherited cancer, Congenica is expanding its platform into new indications such as somatic cancer, next generation non- invasive pre-natal diagnosis and wellness, helping to deliver a future where clinical genomics is fully integrated into healthcare.
Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
www.congenica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005517/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Congenica
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자, 케이뱅크와 손잡고 ‘세상 편한 AI 라이프 챌린지박스’ 선보여 - 뉴스와이어
- 뚝섬·송현광장, 열린 조각 전시장으로 변신… ‘서울조각전시+’ 개최, 조각 73점 전시 - 뉴스와
- 예술시장 진입을 위한 역량 강화 프로그램 ‘2024 청년예술가 역량강화 교육 기·성악 부문’ 참
- LS일렉트릭-유니슨, 국산 풍력발전 기술경쟁력 강화 맞손 - 뉴스와이어
- 롯데건설, 안양 종합운동장 북측 재개발정비사업 수주 - 뉴스와이어
- 투썸플레이스, 비비와 함께한 ‘아박’ 광고 조회수 1000만 뷰 돌파 - 뉴스와이어
- 아로마티카, 국내 뷰티 브랜드 최초 SBTi 승인 획득 - 뉴스와이어
- 대웅제약-KMI, 19그램의 혁신 모비케어로 심전도 검사 개념 바꾼다 - 뉴스와이어
- LIG넥스원, 합동군사대와 ‘미래 국방 군사전문가 육성 MOU’ 체결 - 뉴스와이어
- 김녕해녀마을-소닉이엔엠코리아-위드라이크, 제주도 김녕해녀마을 홍보 위해 협력 - 뉴스와이어